IXHLNasdaqPharmaceutical PreparationsFiscal year ends June 30

Incannex Healthcare Inc.

Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 25, 2026

$2.76−0.06 (-2.13%)

Close on Oct 19, 2026

Market cap: $33.89M
P/E (TTM): –
Dividend yield: –

Incannex Healthcare Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-06-30	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30	FY 2020 2020-06-30
Revenue	0	0.09	0.01	–	–	1.90	0.60
Cost of Revenue	–	–	–	–	0.01	0.91	0.45
Gross Profit	–	–	–	–	–	0.99	0.15
Research & Development	5.21	11	13	6.31	5.37	4.75	2.11
General & Administrative	18	13	17	8.01	0.28	0.10	0.46
Advertising Expenses	–	–	–	1.85	2.75	4.35	0.41
Operating Expenses	23	24	30	50	16	13	–
Operating Income	-23	-24	-30	-50	–	–	–
Interest Expense	0	0.30	–	–	–	–	–
Interest & Investment Income	0.02	0.06	0.21	0.24	–	–	–
Income from Equity Investments	-0.04	0	–	–	–	–	–
Other Non-Operating Income	3.73	-23	12	0.86	–	–	–
Pretax Income	-19	-47	-18	-49	-15	-11	-3.93
Income Tax Expense	0	0	0.03	–	–	–	–
Income from Continuing Operations	–	–	–	-20	-15	-11	-3.93
Income from Discontinued Operations	–	–	–	–	–	–	-0.77
Net Income incl. Noncontrolling Interests	–	–	–	-20	-15	-11	-4.70
Net Income	-19	-47	-18	-49	–	–	–
EPS (Basic)(per share)	-1.66	-40.82	-34.50	-99.60	-37.50	-34.80	-20.70
EPS (Diluted)(per share)	-1.66	-40.82	-34.50	-99.60	-37.50	-34.80	-17.10
Shares Outstanding (Basic, Weighted)(shares)	12	1.15	0.54	0.51	40	–	–
Shares Outstanding (Diluted, Weighted)(shares)	12	1.15	0.54	0.51	40	–	–
EBITDA	-23	-24	-30	-50	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2026

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2026: -47.8%

Financial strength

Current ratio: 48.81
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 4538.3%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.50
Dividend yield: –